Press Releases
AmLexin™ Studies for Delayed Onset Muscle Soreness and Joint Health
Featured Prominently in Peer-Reviewed Scientific Publications
March 2019
Two recently concluded studies on Unigen’s joint health ingredient AmLexin™ have been published with particular recognition in scientific periodicals Nutrition and the Journal of Exercise Nutrition and Biochemistry. AmLexin™ is a patented botanical composition that contains a standardized blend of bioflavonoids from the heartwood of Acacia catechu and the root bark of Morus alba.
UNIGEN’S UP1307 SKIN CREAM EXCELS IN CLINICAL TRIAL
August 2018
Significant clinical results indicate Unigen’s newest skin care ingredient, UP1307, is effective in promoting skin hydration, firmness, and elasticity, with associated improvement in cellulite appearance. In the recently concluded clinical trial, UP1307 resulted in visibly superior results compared to similar cellulite products…
RESEARCH ABSTRACT PRESENTED AT 2018 ANNUAL ASP MEETING
July 2018
TRITERPENOID SAPONINS FROM THE ROOTS OF GLYCYRRHIZA GLABRA
Qingyao Shou1, Ping Jiao1, Mei Hong1, Qi Jia1, Indra Prakash2*, Sangphyo Hong2, Bin Wang2, Gil Ma2, Allison Bechman2
1Unigen USA, 2121 South State St., Suite 400, Tacoma, WA 984052 The Coca-Cola Company, One Coca-Cola Plaza North West, Atlanta, GA 30313
New AmLexin™ data validates increased exercise recovery and reduced DOMS
March 2018
Unigen’s next generation joint protection product AmLexin™ has been clinically proven to aggressively support exercise recovery and within 1 to 3 days reduce delayed onset of muscular soreness post-exercise in healthy adults…
Health Canada Approves Fast Acting Health Claims for Univestin®
September 2017
Unigen’s superior regulatory and science teams are adding value to Canadian market joint care brands with the announcement of Health Canada’s approval of 3 day and 5 day fast acting health claims for Univestin®, Unigen’s premier joint health ingredient…
Unigen and Institute of Chinese Materia Medica collaborate on DNA barcoding of PhytoLogix™ plants
September 2017
Unigen is partnering with China’s top tier Institute of Chinese Materia Medica to complete DNA barcoding of botanicals and marines in Unigen’s proprietary PhyoLogix™ collection…
New Publication on Univestin® Looks at Effects on Specific Systems
April 2016
Unigen, Inc. has published a study showing Univestin has no adverse effects on the Cardiovascular, Respiratory and Central Nervous Systems…
Extensive Safety Testing Continues for Univestin®
March 2016
Unigen, Inc. publishes extensive 26-week toxicity study; providing further validation for Univestin’s long-term safety…
New Developments in Joint Health Provided by Unigen, Inc.
February 2016
Unigen, Inc. continues to fulfill their mission to bring the best of nature to humankind with new ingredients offerings and more research.
Unigen Announces Relaunch of Univestin®
August 2015
Univestin® proprietary joint health ingredient debuts with new branding, logo, marketing materials all designed to promote the Univestin Triple Play: Accelerated Action, Lasting Comfort, Long-term Safety…
Univestin® Reproductive Toxicity Studies Published
August 2015
Unigen continues to add to the extensive body of research surrounding Univestin®, their innovative joint health ingredient, with new studies on the effects of the compound on reproduction in rats. Unigen performed 3 separate but related studies, labeled as Part-I through III. Each part addresses a different aspect of fertility, reproduction and development…
Unigen Hires Vice President of Sales & Marketing
June 2015
Unigen, Inc. announced today that Grant Bergstrom joined the company to help further expand the awareness and distribution of the firm’s scientifically proven ingredients.
Rodney Storms Joins Unigen as Regional Sales Director
June 2015
Unigen, Inc. announced today that Rodney Storms joined the company as Regional Sales Director…
Unigen Names Regan Miles as President and CEO
April 2015
Unigen, Inc. announced today that Regan Miles has been selected to lead the company as President and CEO.